Daniel Arlein has already had COVID-19. In March, the 36-year-old small business owner and DJ, who lives in Brooklyn, tested positive for the viral infection and suffered through two weeks of flu-like symptoms.
Arlein has since recovered, and while hes still being careful avoiding leaving the house, washing his hands more often and wearing a face mask he cant help feeling a bit relieved to have already had the infection.
The only way its helping me is psychologically, to be able to go out in the world and still be careful but not be freaked out that Im going to get sick, he said. I have no idea if I will get sick again. I feel like I wont, but I have no idea if I can get it again.
Most people understand immunity to mean that once a person has been exposed to a disease, they cant get it again. Its an easy concept to grasp, and some people have hoped that widespread immunity could be the way out of this pandemic: If enough of the population becomes immune to the disease, the spread would be stopped, since the virus would run out of new, susceptible targets. The herd of immune people would protect everyone.
But getting to herd immunity without a vaccine isnt as simple as the idea itself. A number of variables can affect when herd immunity is reached and what it costs to get there and they vary depending on the disease. How infectious is the disease? How deadly is it? And how long do people stay immune once theyve gotten it? Adjusting any of these variables can drastically change the outcome of this equation. You can probably sense where this is heading
Weve built a very simplified version of how those variables interact. (Youll see just how simple in the methodology beneath the simulator.) To be clear, this is not about COVID-19 itself instead, our calculator shows how a theoretical disease were calling Fictionitis would play out in a population that has never encountered it before and does nothing to try to stop it.
Youll notice that each variable plays a role in setting a herd immunity threshold and reaching it.
The more people a person with Fictionitis infects on average, the higher the herd immunity threshold rises, but the faster spread also means that the threshold is reached more quickly. That, of course, can lead to a huge portion of the population getting ill at once, which would overwhelm hospitals. Unless the death rate is extremely low, that would be a devastating mix. A disease that doesnt spread as readily will stick around for longer, but it helps maintain a flatter curve.
If you shortened the immunity duration, you may have also seen that the blue bar showing how much of the population is susceptible rose again even after the herd immunity threshold had been crossed. Thats because if immunity fades while the disease is still active, people who were previously immune once again become at risk for infection. Herd immunity only truly works while the recovered population has immunity to the disease.
For COVID-19, of course, we cant change these variables, and we still havent nailed down their exact values, anyway. What we do know so far paints a stark picture: This disease is too deadly, too contagious and too new to depend on post-infection immunity (as opposed to immunity via vaccination) as a solution. Naturally acquired herd immunity is not the answer.
If everyone in a population is immune to the infection, it cant spread. But we can prevent a diseases spread even without everyone being immune. If enough people are immune, the infection is unlikely to spread to big swaths of vulnerable people because those who are immune, the herd, protect them. The more people who are immune, the more likely it is that infectious people will only come into contact with people who cannot be infected, ending the spread. This creates a societal barrier between the infectious and the vulnerable.
The moment when herd immunity kicks in depends on how contagious the pathogen is, which is measured by what experts call the basic reproduction number, or R0 (pronounced R naught). The R0 is simply the average number of people an infectious person will spread the disease to in a population where no one is immune, so an R0 of 3 would mean an infected person spreads the disease to, on average, three other people while theyre contagious.
The higher the R0, the higher the proportion of the population that needs to be immune to stop its spread. This is known as the herd immunity threshold, and the formula for finding it is actually pretty straightforward: 1 1/R0. For a really contagious disease like measles, which has an R0 between 12 and 18, 93 to 95 percent of the population needs to be immune to stop the spread (this is why the U.S. has had recent measles outbreaks when vaccination rates dropped even slightly).
The higher the proportion in a population that is infected, the fewer places there are for that virus to go, the fewer people are susceptible to being transmitted, said Greta Bauer, an epidemiologist and biostatistician at Western University in Ontario, Canada. That makes sense, right? If one person, on average, infects two other people but half the population is immune, theyre only going to be able to infect one other person.
For COVID-19, were still not certain what the R0 is, so we dont yet know what the herd immunity threshold is. For now, its estimated to be anywhere from 70 to 90 percent. But heres the problem: To reach even the lower end of that range naturally in the U.S. imagine giving up on any interventions and just letting the disease run its course 230 million Americans would eventually become infected and, depending on the fatality rate (more on that later), millions could die.
And reaching herd immunity as the outbreak is raging is a completely different scenario than, for example, doing so after a vaccine has been created. With a vaccine, you can immunize people before theyve encountered the virus, so by the time the virus gets to a vaccinated population, it has nowhere to spread. But in an active outbreak, even once the herd immunity threshold is reached, the infection keeps going. It takes time for the spread of the disease to crest because, for a while at least, many contagious people will each still infect a small number of vulnerable people, which means even more people will get sick and die. Its a phenomenon known as overshoot.
The disease sort of stops increasing at the point when you reach herd immunity, but theres still lots and lots of people infected. It only slowly goes down, and on its way down, [it] infects another third of the population, said Richard Neher, an evolutionary biologist at the University of Basel in Switzerland. If you drive a car and suddenly you switch off the engine, it doesnt stop instantly.
So think of crossing the herd immunity threshold as determining the fate of the disease (its now bound to die out) rather than its status (its dead).
Since the new coronavirus is highly contagious (meaning a large percentage of the population would have to get it to slow its spread), the human toll of reaching herd immunity without a vaccine would be staggering. And thats assuming that once a person gets sick, they stay immune for a long time. But at this point, we dont know if thats the case.
To reach that herd immunity threshold we either need a vaccine, or we need a lot of people like Arlein who have had the virus and are now immune. Except we dont actually know if Arlein, or anyone else, is really immune.
Typically, when we encounter a new pathogen, our immune system mounts a defense that includes producing antibodies to fight off the infection. Afterward, some of those antibodies and immune cells hang around, allowing our body to remember the offending microbe and more easily fend it off in the future.
The vast majority of anything that you or I have been infected with in our lives, our immune system has developed immunity to and remembers, said Shane Crotty, an immunologist at the La Jolla Institute for Immunology in California. There are definitely exceptions, but thats the norm.
Those exceptions are why experts, including the World Health Organization, cant presume that having had COVID-19 means you cant get it again, even though antibodies have been detected in recovered patients.
The presence of antibodies, everybody thinks that means immunity, but I study HIV and theres a huge antibody response to HIV, and its never able to neutralize that virus, Bauer said.
Researchers have begun trying to find out how much protection COVID-19 antibodies give people whove recovered from the disease. Theres a chance that the immune response from COVID-19 is enough to prevent someone from getting sick again, but not necessarily from getting infected, which means they could still be contagious to others, according to Crotty.
Its likely COVID-19 confers at least some immunity, though. For one, there are no confirmed cases of someone getting COVID-19 twice. Early reports from South Korea drew a lot of attention after patients tested positive for the virus again weeks after having recovered, but researchers later said that dead virus fragments from the original infection likely triggered the positive tests, rather than a second infection. One early study from China which has not yet been peer reviewed, so take it with an extra grain of salt also measured neutralizing antibodies in 94 percent of patients.
Previous research done on similar coronaviruses, like the ones that cause SARS and MERS, also offers some promising signs. In a mouse study testing a SARS vaccine, for example, researchers stimulated an immune response that staved off a dose of the virus.
But why would we fail to become immune to a disease? There are a few things that could be happening. Our bodies could stop short of completely killing off the virus in the first place, allowing it to lie dormant and reemerge later (thats the case with HIV). The virus could evolve enough that our old antibodies wont work anymore, whether we got them from natural exposure or a vaccine (this is what the seasonal flu does, and its part of why we need a new vaccine every year). Or the immune response we produce could just fade too quickly, making us susceptible to reinfection almost immediately.
With the new coronavirus, theres not much evidence that either of the first two scenarios is in play, but the third possibility that our immunity fades quickly remains an open question, and one we wont be able to answer until more time has passed. Coronaviruses also cause common colds, after all, and humans seem perpetually susceptible to those. In one oft-cited study, for example, people were given a dose of a cold-causing coronavirus, got sick and recovered, then were given another dose a year later. Most of the patients got reinfected, showing how quickly their immunity waned. (And most of them didnt get sick, which opens up a whole new barrel of fun: If COVID-19 works the same way, some people who had the disease and recovered could wind up picking up and spreading the novel coronavirus again despite not being symptomatic.)
One reason is because your immune system just doesnt remember all things equally, and to some extent that memory is tied to how severe the initial infection was, Crotty said.
That said, for SARS and MERS, both of which were also caused by coronaviruses, immune memory cells were detected in patients several years after infection, though because those outbreaks have ended, we dont know if those immune cells would protect against reinfection.
The only way to know if COVID-19 immunity lasts for, say, 10 years is to wait until a decade has passed and see if anyone who was infected once ever got reinfected. (Were just full of good news, arent we?)
Even if it turns out that infected people become immune for some period of time, we still arent close to herd immunity solving our COVID-19 problem for us. So few people have had the disease that were nowhere near herd immunity yet, and the fatality rate is so high that closing that gap would be devastating.
Eventually, reliable serological tests, which detect antibodies, can be administered to large samples of the population. That will give us a better sense of how many people actually had the infection, and thus the diseases true fatality rate. There was some hope that these serological surveys would reveal the disease was much more widespread and therefore way less deadly than we thought. If, for example, you have 50 deaths in a community and 1,000 recorded cases, the fatality rate is 5 percent (50 out of 1,000). But if a serological survey of that community later revealed that there were actually 3,000 cases, that fatality rate drops to 1.7 percent.
Unfortunately, early serological surveys suggest the fatality rate isnt low enough to offer us much comfort.
In the U.S., there have been 81,507 deaths as of May 12. For a fatality rate of 0.1, the same as the seasonal flu, wed have to find out that 81.5 million Americans, or nearly a quarter of the U.S. population, had already had COVID-19. But based on early serological surveys, the World Health Organization says its likely that only about 2 to 3 percent of the population has been exposed so far.
Some serological surveys have reported wildly different estimates of how many people may be immune. A recent survey in California, for example, found that something like 2 to 4 percent of the population had antibodies, while studies in Germany and Massachusetts found antibodies in 15 to 30 percent of those tested.
One reason for these huge variations could be that rates are genuinely higher in hotspots. Indeed, in New York, the hardest-hit city on the planet, as much as 21 percent of the population may have already been exposed, according to preliminary results from a serological survey. But if even in New York, less than a quarter of the population has antibodies, its pretty unlikely that levels are nearly that high in the rest of the country. And New York has also seen a huge number of deaths: at least more than 19,563 as of May 12. Even if this early estimate is correct and 21 percent of New Yorks 8.4 million residents have already been infected, that comes out to 1.8 million people, which still puts the current fatality rate at 1.1 percent, or more than 10 times that of the seasonal flu.
Looking at what percentage of the population might actually have been infected, the numbers of the cases are much higher and the case fatality rate looks like it might be around half a percent, said Jeremy Rossman, a virologist at the University of Kent. People say, Oh thats a trivial number, its minuscule. But, when you think about, say, the population of the United States, 0.5 percent is a tremendous number, and these are peoples lives.
The other potential explanation for why those serology survey results are all over the map is there may be problems with the way they were conducted. None of the papers mentioned above have been published in peer-reviewed journals yet, and many experts have raised concerns about false positives and how people were recruited for studies, suggesting even these low levels might be overestimating the true prevalence of the disease.
So lets go back to that 70 percent herd immunity threshold. If the fatality rate is around 0.5 and 70 percent of Americans have to get sick before their immunity starts protecting others, that means more than 1.1 million people would die. In New York, even having 21 percent of the population exposed, if that serological survey is accurate, has overrun hospitals and led to the death of one in every 400 New Yorkers, while the vast majority of the population remains susceptible.
Thats the cost of getting to 20 percent, said Emma Hodcroft, a postdoctoral epidemiology researcher at the University of Basel in Switzerland. It really illustrates the price youre going to pay if you want to get up to the 60 percent or 70 percent that youll need for herd immunity, and I hope it really illustrates why that just isnt a feasible plan.
Read the original post:
Without A Vaccine, Herd Immunity Wont Save Us - FiveThirtyEight
- World Health Organization reference values for human semen characteristics [Last Updated On: August 17th, 2024] [Originally Added On: April 6th, 2010]
- Economic consequences of overweight and obesity in infertility: a framework for evaluating the costs and outcomes of fertility care [Last Updated On: August 17th, 2024] [Originally Added On: April 6th, 2010]
- Maternal metabolism and obesity: modifiable determinants of pregnancy outcome [Last Updated On: August 17th, 2024] [Originally Added On: April 6th, 2010]
- Brain imaging studies of appetite in the context of obesity and the menstrual cycle [Last Updated On: August 17th, 2024] [Originally Added On: April 6th, 2010]
- The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis [Last Updated On: August 17th, 2024] [Originally Added On: April 6th, 2010]
- Options for fertility preservation in prepubertal boys [Last Updated On: August 17th, 2024] [Originally Added On: April 6th, 2010]
- Xenografting of testicular tissue from an infant human donor results in accelerated testicular maturation [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Karyotype of miscarriages in relation to maternal weight [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Endoglandular trophoblast, an alternative route of trophoblast invasion? Analysis with novel confrontation co-culture models [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Regulation of extravillous trophoblast invasion by uterine natural killer cells is dependent on gestational age [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Functional regulation of thymic stromal lymphopoietin on proliferation and invasion of trophoblasts in human first-trimester pregnancy [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Functional attenuation of human sperm by novel, non-surfactant spermicides: precise targeting of membrane physiology without affecting structure [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Characteristics indicating adenomyosis coexisting with leiomyomas: a case-control study [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Cumulative ongoing pregnancy rate achieved with oocyte vitrification and cleavage stage transfer without embryo selection in a standard infertility program [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Pregnancy outcome in female childhood cancer survivors [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Offering excess oocyte aspiration and vitrification to patients undergoing stimulated artificial insemination cycles can reduce the multiple pregnancy risk and accumulate oocytes for later use [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Who should pay for assisted reproductive techniques? Answers from patients, professionals and the general public in Germany [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Sperm donor limits that control for the 'relative' risk associated with the use of open-identity donors [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Long-term cryostorage of sperm in a human sperm bank does not damage progressive motility concentration [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Screening for biomarkers of spermatogonia within the human testis: a whole genome approach [Last Updated On: August 17th, 2024] [Originally Added On: April 14th, 2010]
- Avoiding transgenerational risks of mitochondrial DNA disorders: a morally acceptable reason for sex selection? [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Cross border reproductive care in six European countries [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Morphometric dimensions of the human sperm head depend on the staining method used [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- ESX1 gene expression as a robust marker of residual spermatogenesis in azoospermic men [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Innovative virtual reality measurements for embryonic growth and development [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Consecutive or non-consecutive recurrent miscarriage: is there any difference in carrier status? [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- A longitudinal study of contraception and pregnancies in the same women followed for a quarter of a century [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Direct proportional relationship between endometrioma size and ovarian parenchyma inadvertently removed during cystectomy, and its implication on the management of enlarged endometriomas [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Altered aquaporin expression in women with polycystic ovary syndrome: hyperandrogenism in follicular fluid inhibits aquaporin-9 in granulosa cells through the phosphatidylinositol 3-kinase pathway [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Fast-release orodispersible tramadol as analgesia in hysterosalpingography with a metal cannula or a balloon catheter [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Xenotransplantation of cryopreserved human ovarian tissue into murine back muscle [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Predictors of psychological distress in patients starting IVF treatment: infertility-specific versus general psychological characteristics [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Psychological adjustment, knowledge and unmet information needs in women undergoing PGD [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Mothers of IVF and spontaneously conceived twins: a comparison of prenatal maternal expectations, coping resources and maternal stress [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Psychological well-being and sexarche in women with polycystic ovary syndrome [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Is human fecundity declining in Western countries? [Last Updated On: August 17th, 2024] [Originally Added On: May 20th, 2010]
- Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis [Last Updated On: August 17th, 2024] [Originally Added On: June 5th, 2010]
- Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation [Last Updated On: August 17th, 2024] [Originally Added On: June 5th, 2010]
- Human studies on genetics of the age at natural menopause: a systematic review [Last Updated On: August 17th, 2024] [Originally Added On: June 5th, 2010]
- Beyond oxygen: complex regulation and activity of hypoxia inducible factors in pregnancy [Last Updated On: August 17th, 2024] [Originally Added On: June 5th, 2010]
- Current knowledge of the aetiology of human tubal ectopic pregnancy [Last Updated On: August 17th, 2024] [Originally Added On: June 5th, 2010]
- Economic contraction and birth outcomes: an integrative review [Last Updated On: August 17th, 2024] [Originally Added On: June 5th, 2010]
- Teratogenic mechanisms of medical drugs [Last Updated On: August 17th, 2024] [Originally Added On: June 5th, 2010]
- Levels of semenogelin in human spermatozoa decrease during capacitation: involvement of reactive oxygen species and zinc [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Apoptosis and meiotic segregation in ejaculated sperm from Robertsonian translocation carrier patients [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- In humans, zona pellucida glycoprotein-1 binds to spermatozoa and induces acrosomal exocytosis [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Variants of the EPPIN gene affect the risk of idiopathic male infertility in the Han-Chinese population [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Epidermal clitoral inclusion cysts: not a rare complication of female genital mutilation [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Single versus double intrauterine insemination in multi-follicular ovarian hyperstimulation cycles: a randomized trial [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Soluble HLA-G is an independent factor for the prediction of pregnancy outcome after ART: a German multi-centre study [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Obstetric outcomes after transfer of vitrified blastocysts [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Occasional involvement of the ovary in Ewing sarcoma [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Y chromosome microdeletions, sperm DNA fragmentation and sperm oxidative stress as causes of recurrent spontaneous abortion of unknown etiology [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Development and preliminary validation of the fertility status awareness tool: FertiSTAT [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Xenotransplantation of human ovarian tissue to nude mice: comparison between four grafting sites [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Involvement of CFTR in oviductal HCO3- secretion and its effect on soluble adenylate cyclase-dependent early embryo development [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Effect of endometriosis on the protein expression pattern of follicular fluid from patients submitted to controlled ovarian hyperstimulation for in vitro fertilization [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Activin A regulates trophoblast cell adhesive properties: implications for implantation failure in women with endometriosis-associated infertility [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Clinical significance of sperm DNA damage in assisted reproduction outcome [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Fall in implantation rates following ICSI with sperm with high DNA fragmentation [Last Updated On: August 17th, 2024] [Originally Added On: June 17th, 2010]
- Prevalence of unsuspected uterine cavity abnormalities diagnosed by office hysteroscopy prior to in vitro fertilization [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- Fertility after autologous ovine uterine-tubal-ovarian transplantation by vascular anastomosis to the external iliac vessels [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- Uterus transplantation in the baboon: methodology and long-term function after auto-transplantation [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- Prestimulation parameters predicting live birth in anovulatory WHO Group II patients undergoing ovulation induction with gonadotrophins [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- Transfer of a selected single blastocyst optimizes the chance of a healthy term baby: a retrospective population based study in Australia 2004-2007 [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- Disclosure patterns of mode of conception among mothers and fathers-5-year follow-up of the Copenhagen Multi-centre Psychosocial Infertility (COMPI) cohort [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- A decade of sperm washing: clinical correlates of successful insemination outcome [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- Sperm DNA integrity in cancer patients before and after cytotoxic treatment [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- Speriolin is a novel human and mouse sperm centrosome protein [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- No influence of body mass index on first trimester fetal growth [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]
- HLA sharing among couples appears unrelated to idiopathic recurrent fetal loss in Saudi Arabia [Last Updated On: August 17th, 2024] [Originally Added On: July 21st, 2010]